Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | METAP2 | P50579 | 5/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4193484 | 0.90 | KDM4E (0.47) | KDM4EPKMLMNAPOLBPTGES2 | |
| SCHEMBL4200042 | 0.89 | KDM4E (0.46) | KDM4EPKMLMNAPOLBALDH1A1 | |
| SCHEMBL4194882 | 0.88 | KDM4E (0.41) | KDM4EPKMLMNAPOLBALDH1A1 | |
| SCHEMBL4189902 | 0.84 | NPC1 (0.45) | KDM4EPKMALDH1A1MAPT | |
| SCHEMBL12050344 | 0.83 | KDM4E (0.55) | KDM4EPKMLMNAPOLBPTGES2 | |
| SCHEMBL4710006 | 0.82 | KDM4E (0.46) | KDM4EPKMLMNAPOLBPTGES2 | |
| SCHEMBL4204377 | 0.82 | KDM4E (0.43) | KDM4EPKMLMNAPOLBPTGES2 | |
| SCHEMBL4184516 | 0.80 | KDM4E (0.53) | KDM4EPKMLMNAPOLBPTGES2 | |
| SCHEMBL4202174 | 0.80 | KDM4E (0.53) | KDM4EPKMLMNAPOLBPTGES2 | |
| SCHEMBL4193899 | 0.80 | PKM (0.53) | KDM4EPKMLMNAPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879877-B1 | ANTIMICROBIAL AGENTS | RANBAXY LAB LTD (IN) | 2013-01-02 | — | — | EP | claimed |
| US-8076370-B2 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2011-12-13 | — | — | US | claimed |
| US-20090215764-A1 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2009-08-27 | — | — | US | claimed |
| EP-1879877-B1 | ANTIMICROBIAL AGENTS | RANBAXY LAB LTD (IN) | 2013-01-02 | — | — | EP | disclosed |
| US-8076370-B2 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2011-12-13 | — | — | US | disclosed |
| US-20090215764-A1 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2009-08-27 | — | — | US | disclosed |
| EP-1879877-A2 | ANTIMICROBIAL AGENTS | Ranbaxy Laboratories Limited (IN) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006117762-A2 | ANTIMICROBIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215764-A1 | Antimicrobial agents | TUFM, RPS17, HARS1 | KDM4E 3328/4885PKM 1855/4885LMNA 2332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.